Although a clearly defined pattern of tumor evolution has not yet been described in GBM, TP53 gene mutations have been recently proposed as a marker of subclonal heterogeneity (Tcga, 2008; Brennan et al., 2013; Wang et al., 2016). This evidence concerns the gene TP53 and glioblastoma.